Adverse reactions and their mechanisms from nimesulide

Nimesulide - Actions and Uses

Volumn , Issue , 2005, Pages 315-415

  Bjarnason, I ^a   Bissoli, F ^b   Conforti, A ^c   Maiden, L ^a   Moore, N ^d   Moretti, U ^c   Rainsford, K D ^e   Takeuchi, K ^a   Velo, G P ^f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Divisione Clinica Medica   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^f Policlinico   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920188384     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-7643-7410-1_6     Document Type: Chapter

References (402)

1. Rainsford KD, Velo GP (eds) (1983) Side-Effects of Anti-Inflammatory/Analgesic Drugs. Raven Press, New York
2. Rainsford KD, Velo GP (eds) (1987) Side-Effects of Anti-Inflammatory Drugs. Clinical and Epidemiological Agents. MTP Press, Lancaster
3. Rainsford KD, Velo GP (eds) (1992) Side-Effects of Anti-Inflammatory Drugs. III. Kluwer Academic Publishers, Lancaster
4. Rainsford KD (1999) Profile and mechanisms of gastrointestinal and other side-effects from NSAIDs. Am J Med 107(6 A):27S-36S
5. Simon RA, Namazy J (2003) Adverse reactions to aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) Clin Rev Allergy Immunol 24(3):239-252
6. Day R (2003) COX-2: where are we in 2003? Distinction from NSAIDs becoming blurred. Arthritis Res Ther 5(3):116-119
7. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F (2003) Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs. Clin Rev Allergy Immunol 24(2):125-136
8. Rainsford KD (1992) Mechanisms of rash formation and related skin conditions induced by non-steroidal anti-inflammatory drugs. In: KD Rainsford, GP Velo (eds): Side-Effects of Anti-Inflammatory Drugs-3. Kluwer Academic Publishers, Lancaster, 287-301
9. Sturkenboom M, Nicolosi A, Cantarutti L, Mannino S, Picelli G, Scamarcia A, Giaquinto C; NSAIDs Paediatric Research Group (2005) Incidence of mucocutaneous reactions in children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or nonopioid analgesics. Pediatrics 116:e26-33 [e-print ahead of publication]
10. Rainsford KD (1999) Relationship of nimesulide safety to its pharmacokinetics: Assessment of adverse Reactions. Rheumatology (Oxford) 38(Suppl):4-10
11. De Abajo F, Montero D, Madurga M, Garcia Rodriguez LA (2004) Acute and clinically relevant drug-induced liver injury: A population-based case-control study. Br J Clin Pharmacol 58:71-80
12. Van Steenbergen W, Peeters P, De Bondt J, Staessen D, Buscher H, Laporta T et al. (1998) Nimesulide-induced acute hepatitis: Evidence from six cases. J Hepatol 29:135-141
13. Schattner A, Sokolovskaya N, Cohen J (2000) Fatal hepatitis and renal failure during treatment with nimesulide. J Intern Med 247:153-155
14. Weiss P, Mouallem M, Bruck R, Hassin D, Tanay A, Brickman CM et al. (1999) Nimesulideinduced hepatitis and acute liver failure. Isr Med Assoc J 1:89-91
15. McCormick PA, Kennedy F, Curry M, Traynor O (1999) COX 2 inhibitor and fulminant hepatic failure. Lancet 353:40-41
16. Elmalem E (2000) Nimesulide, clavulanic acid and hepatitis. J Intern Med 248:168-169
17. Andrade RJ, Lucena MI, Fernandez MC, Gonzalez M (2000) Fatal hepatitis associated with nimesulide. J Hepatol 32:174
18. Romero-Gomez M, Nevado Santos M, Otero Fernandez MA, Fovelo MJ, Suarez-Garcia E, Castro Fernandez M (1999) Acute cholestatic hepatitis induced by nimesulide. Liver 19:164-165
19. Ferreiro C, Vivas S, Jorquera F, Dominguez AB, Espinel J, Munoz F et al. (2000) Toxic hepatitis caused by nimesulide, presentation of a new case and review of the literature. Gastroenterol Hepatol 23:428-430
20. Rodrigues De Oliveira J, Correia J, Silvestre F, Meirelles A, Bernardo A (2000) Severe acute hepatitis probably induced by nimesulide. Gastroenterol Clin Biol 24:592-593
21. Merlani G, Fox M, Oehen HP, Cathomas G, Renner EL, Fattinger K et al. (2001) Fatal hepatotoxicity secondary to nimesulide. Eur J Clin Pharmacol 57:321-326
22. Sbeit W, Krivoy N, Shiller M, Farah R, Cohen HI, Struminger L et al. (2001) Nimesulideinduced acute hepatitis. Ann Pharmacother 35:1049-1052
23. Macia MA, Carvajal A, Del Pozo JG, Vera E, Del Pino A (2002) Hepatotoxicity associated with nimesulide: Data from the Spanish Pharmacovigilance System. Clin Pharmacol Ther 72:596-597
24. Garcia Rodriguez LA, Perez Gutthann S, Walker AM, Lueck L (1992) The role of nonsteroidal anti-inflammatory drugs in acute liver injury. Br Med J 305:865-868
25. Carson JL, Strom BL, Duff A, Gupta A, Das K (1993) Safety of nonsteroidal antiinflammatory drugs with respect to acute liver disease. Arch Intern Med 153:1331-1336
26. Perez Gutthann S, Garcia Rodriguez LA (1993) The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 4:496-501
27. Garcia Rodriguez LA, Williams R, Derby LE, Dean AD, Jick H (1994) Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 154:311-316
28. Garcia Rodriguez LA, Ruigomez A, Jick H (1997) A review of epidemiologic research on drug-induced acute liver injury using the general practice research database in the United Kingdom. Pharmacotherapy 17:721-728
29. Traversa G, Bianchi C, Da Cas R, Abraha R, Menniti-Ippolito F, Venegoni M (2003) Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal antiinflammatory drugs. Br Med J 327:18-22
30. Press Release (2003) European Medicines Evaluation Agency (EMEA) states that nimesulide is safe and effective. www.nimesulide.net (accessed 16 Sept 2004)
31. Rainsford KD (1998) An analysis from clinico-epidemiological data of the principal adverse events from the COX-2 selective NSAID, nimesulide, with particular reference to hepatic injury. Inflammopharmacology 6:203-221
32. Rainsford KD, Shepherd P (2003) Analysis of the adverse reactions in the liver, renal and urinary systems and gastrointestinal tract from the COX-2 NSAID nimesulide. Report to Helsinn Healthcare SA
33. Lewis SC, Langman M J S, Laporte J-R, Matthews J N S, Rawlins MD, Wiholm B-E (2002) Dose-response relationships between individual non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 54:320-334
34. García-Rodríguez LA, Hernández-Díaz S (2001) Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 12:570-576
35. Henry D, Lim LL-Y, García Rodríguez LA, Pérez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C et al. (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 312:1563-1566
36. Hernández-Diaz S, García Rodriguez LA (2000) Association between nonsteroidal antiinflammatory drugs and upper gastrointestinal tract bleeding and perforation: An overview of epidemiological studies published in the 1990s. Arch Int Med 160:2093-2099
37. Traversa G, Walker AM, Ippolito FM, Caffari B, Capurso L, Dezi A, Koch M, Maggini M, Alegiani SS, Raschetti R (1995) Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs. Epidemiology 6:49-54
38. Menniti-Ippolito F, Maggini M, Raschetti R, Da Cas R, Traversa G, Walzer AM (1998) Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy. Eur Clin Pharmacol 54:393-397
39. García Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L (1998) Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 158:33-39
40. Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R (2004) Upper gastrointestinal bleeding associated with the use of NSAIDs: Newer versus older agents. Drug Saf 27:411-420
41. Trechot P, Gillet P, Gay G, Hanesse B, Netter P, Castot A, Larrey D (1996) Incidence of hepatitis induced by non-steroidal anti-inflammatory drugs (NSAID) Ann Rheum Dis 55:936
42. Walker AM (1997) Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum 40:201-208
43. Boelsterli UA (2002) Mechanisms of NSAID-induced hepatotoxicity: Focus on nimesulide. Drug Saf 25:633-648
44. Schattner A, Sokolovskaya N, Cohen J (2000) Fatal hepatitis and renal failure during treatment with nimesulide. J Intern Med 247:153-155
45. Gatti S, Bertazzoli M (2002) Evaluation of isolated case reports on hepatotoxicity. Eur J Clin Pharmacol 57:919-920
46. Merlani G, Fox M, Oehen HP, Cathomas G, Renner EL, Fattinger K, Schneemann M, Kullak-Ublick GA (2001) Fatal hepatoxicity secondary to nimesulide. Europ J Clin Pharmacol 57:321-326
47. Macia MA, Carvajal A, Del Pozo JG, Vera E, Del Pino A (2002) Hepatotoxicity associated with nimesulide: data from the Spanish Pharmacovigilance System. Clin Pharmacol Therap 72:596-597
48. Conforti A, Leone R, Moretti U, Mozzo F, Velo GP (2001) Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: Results of spontaneous reporting from a Northern Italian area. Drug Saf 24:1081-1090
49. Agence francaise de securitè sanitarie des produits de Santé. www.Agmed.sante.gouv.fr (16 June 2003)
50. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M (2003) Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal antiinflammatory drugs. Br Med J (5) 327:18-22
51. Krähenbühl S, Reichen J (2000) Drug hepatotoxicity. In: Bacon BR, Di Bisceglie, AM (eds): Liver disease diagnosis and management. Churchill Livingstone, New York, 294-309
52. Papachristou GI, Demetris AJ, Rabinovitz M (2004) Acute cholestatic hepatitis associated with long-term use of rofecoxib. Dig Dis Sci 49:459-461
53. Grieco A, Miele L, Giorgi A, Civello IM, Gasbarrini G (2002) Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother 36:1887-1889
54. Svensson CK, Cowen EW, Gaspari AA (2001) Cutaneous drug reactions. Pharmacol Rev 53:357-379
55. Roujeau J-C, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F et al. (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. New Engl J Med 333:1600-1607
56. Mockenhaupt M, Kelly JP, Kaufman D, Stern RS; SCAR Study Group (2003) The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: A multinational perspective. J Rheumatol 30:2234-2240
57. Schmutz JL, Barbaud A, Trechot P (2004) Toxic epidermal necrolysis and celecoxib Annal Dermatol Venerol 131:107
58. Perna AG, Woodruff CA, Markus RF, Hsu S (2003) Toxic epidermal necrolysis as a complication of treatment with celecoxib. Dermatol Online J 9:25
59. Giglio P (2003) Toxic epidermal necrolysis due to administration of celecoxib (Celebrex) South Med J 96:320-321
60. Anonymous (1993) Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Analysis of reports to the spontaneous reporting system of the Gruppo Italiano Studi Epidemiologici in Dermatologia. Dermatol 186:164-169
61. Nettis E, Di Paola R, Napoli G, Ferrannini A, Tursi A (2002) Benzydamine: An alternative nonsteroidal anti-inflammatory drug in patients with nimesulide-induced urticaria. Allergy 57:442-445
62. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F (2003) Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs. Clin Rev Immunology 24:125-136
63. Strom BL, Carson JL, Morse ML, West SL, Soper KA (1987) The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs. Arthritis Rheum 30:1142-1148
64. Jenkins C, Costello J, Hodge L (2004) Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. Br Med J (21) 328:434
65. Asero R (2000) Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann All Asth Immunol 85:156-157
66. Perez C, Sanchez-Borges M, Capriles E (2001) Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema. J All Asth Clin Immunol 108:1060-1061
67. Perrone MR, Artesani MC, Viola M, Gaeta F, Caringi M, Quaratino D, Romano A (2003) Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal antiinflammatory drugs: A study of 216 patients and literature review. Int Arch All Immunol 132:82-86
68. Gagnon R, Julien M, Gold P (2003) Selective celecoxib-associated anaphylactoid reaction. J All Asth Clin Immunol 111:1404-1405
69. Grob M, Pichler WJ, Wuthrich B (2002) Anaphylaxis to celecoxib. Allergy, 57:264-265
70. Valero Santiago A, Gonzalez-Morales MA, Marti Guadano E (GETNIA) Grupo de Estudio de Tolerancia a Nimesulida en pacientes Intolerantes a AINES (2003) Tolerance of nimesulide in NSAID intolerant patients. Allergy 58(4):367-368
71. Senna GE, Passalacqua G, Andri G, Dama AR, Albano M, Fregonese L, Andri L (1996) Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs. Drug Saf 14:94-103
72. Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z (2004) Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma 41:67-75
73. Nettis E, Marcandrea M, Ferrannini A, Tursi A (2001) Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema. Immunopharmacol Immunotoxicol 23:343-354
74. Rossoni G, Berti F, Buschi A, Villa LM, Bella DD (1993) New data concerning the antianaphylactic and antihistaminic activity of nimesulide. Drugs 46(Suppl 1):22-28
75. Griffin MR, Yared A, Ray WA (2000) Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol (1) 151:488-496
76. Ravnskov U (1999) Glomerular, tubular and interstitial nephritis associated with nonsteroidal antiinflammatory drugs. Evidence of a common mechanism Br Clin Pharmacol 47:203-210
77. Clinard F, Sgro C, Bardou M, Hillon P, Dumas M, Kreft-Jais C, Escousse A, Bonithon-Kopp C (2004) Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. Eur J Clin Pharmacol 60:279-283
78. Leone R, Conforti A, Ghiotto E, Moretti U, Valvo E, Velo GP (1999) Nimesulide and renal impairment. Eur J Clin Pharmacol 55:151-154
79. Schattner A, Sokolovskaya N, Cohen J (2000) Fatal hepatitis and renal failure during treatment with nimesulide. J Intern Med 247:153-155
80. Van Der Niepen P, Janssen Van Doorn K, Van Den Houte K, Verbeelen D (2002) Nimesulide and acute renal failure caused by oxalate precipitation. Nephrol Dialysis Transplant 17:315-316
81. Stollberger C, Finsterer J (2003) Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders. Z Kardiol 92:721-729
82. Garcia Rodriguez LA, Hernandez-Diaz S (2003) Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology 14:240-246
83. Hernandez-Diaz S, Garcia-Rodriguez LA (2001) Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 110(Suppl 3A):20S-27S
84. Topol EJ (2004) Failing the public health - Rofecoxib, Merck, and the FDA. N Engl J Med 351:1707-1709
85. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363:1751-1756
86. Anonymous (2005) FDA discloses safety reviews of COX-2's Arcoxia, Prexige and parecoxib and Vioxx cardiovascular risk is unique to molecule, Pfizer and Novartis tell FDA. "The Pink Sheet" FDC Reports February: 11-13
87. Drazen JM (2005) COX-2 inhibitors - A lesson in unexpected problems. N Engl J Med 352:1131-1132
88. Psaty BM, Furberg CD (2005) COX-2 inhibitors - Lessons in drug safety. N Engl J Med 352:1133-1135
89. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109:2068-2073
90. Brinker A, Goldkind L, Bonnel R, Beitz J (2004) Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging 21:479-484
91. Cho J, Cooke CE, Proveaux W (2003) A retrospective review of the effect of COX-2 inhibitors on blood pressure change. Am J Ther 10:311-317
92. Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351:1709-1711
93. Hernandez MR, Tonda R, Pino M, Serradell M, Arderiu G, Escolar G (2004) Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. Eur J Clin Invest 34:297-302
94. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G (2004) Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 68:341-350
95. Baber SR, Champion HC, Bivalacqua TJ, Hyman AL, Kadowitz PJ (2003) Role of cyclooxygenase-2 in the generation of vasoavtive prostanoids in the pulmonary and systemic vascular beds. Circulation 108:896-901
96. Cesarani R, Carboni L, Germini M, Mainardi P, Passoni A (1993) Antipyretic and platelet antiaggregating effects of nimesulide. Drugs 46(Suppl 1):48-51
97. Shi W, Wang YM, Cheng NN, Chen BY, Li D (2003) Meta-analysis on the effect and adverse reaction on patients with osteoarthritis and rheumatoid arthritis treated with nonsteroidal anti-inflammatory drugs Zhonghua Liu Xing Bing Xue Za Zhi 24:1044-1048
98. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D (2005) The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: a systematic review. Br Med J 329:948-958
99. Wober W (1999) Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide. Rheumatology 38(suppl 1):33-38
100. Shah AA, Thjodleifsson B, Murray FE, Sigthorsson G, Oddson E, Gudjonsson H, Price AB, Fitzgerald DJ, Bjarnason I (2001) A randomised, double blind, double dummy, crossover study of the effects of nimesulide and naproxen on the gastrointestinal tract and an in vivo assessment of their selectivity for cyclooxygenase 1 and 2. Gut 48:339-348
101. Shah AA, Murray FE, Thjodleifsson B et al. (1998) Nimesulide, a selective COX-2 inhibitor, causes less gastrointestinal damage compared with naproxen: a prospective study in human volunteers. Gastroenterology 115:101-109
102. Bjarnason I, Thjodleifsson B (1999) Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: The effect of nimesulide compared with naproxen on the human gastrointestinal tract. Rheumatology 38(suppl 1):24-32
103. Feldman M, McMahon AT (2000) Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 132:134-143
104. Whittle B J R (1992) Unwanted effects of aspirin and related agents on the gastrointestinal tract. In: JR Vane, RM Botting (eds): Aspirin and other Salicylates. Chapman & Hall Medical, London, 465-509
105. Bjarnason I, Hayllar J, Macpherson AJ, Russell AS (1993) Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 104:1832-1847
106. Somasundaram S, Hayllar J, Rafi S, Wrigglesworth J, Macpherson A, Bjarnason I (1995) The biochemical basis of NSAID-induced damage to the gastrointestinal tract: A review and a hypothesis. Scand J Gastroenterol 30:289-299
107. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG et al. (2002) COX-1 and 2, intestinal integrity and pathogenesis of NSAID-enteropathy in mice. Gastroenterology 122:1913-1923
108. Somasundaram S, Sigthorsson G, Price AB, Tavares IA, Rafi S, Mahmud T, Roseth A, Foster R, Macpherson S, Wrigglesworth JM et al. (2000) The relative importance of inhibition of cyclooxygenase and uncoupling of oxidative phosphorylation in the gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. Aliment Pharm Therap 14:639-650
109. Wallace JL, McKnight, Reuter BK, Vergnolle N (2000) Dual inhibition of both cyclooxygenase (COX)-1 and COX-2 is required for NSAID-induced erosion formation. Gastroenterology 119:704-714
110. Hotz-Behofsits CM, Walley M J M, Simpson R, Bjarnason IT (2003) COX-1, COX-2 and the topical effect in NSAID-induced enteropathy. Inflammopharmacology 11:363-370
111. Newberry RD, Stenson WF, Lorenz RG (1999) Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nature Med 5:900-906
112. Bjarnason I, Scarpignato C, Takeuchi J, Rainsford KD (2005) NSAID-induced gastric damage: Do physicochemical properties matter? Submitted
113. Fenn GC (1994) Controversies in NSAID-induced gastroduodenal damage-do they matter? Aliment Pharmacol Ther 8:15-26
114. Walt R (1992) Drug therapy: Misoprostol for the treatment of peptic ulcer and antiinflammatory drug-induced gastroduodenal ulceration. N Engl J Med 327:1575-1580
115. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, Austin PC, Laupacis A (2002) Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs. Br Med J 325:624
116. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A (2004) Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. Br Med J 328:1415-1416
117. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF (1996) Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 156:1530-1536
118. Silverstein FE, Graham GY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis SG (1995) Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Int Med 123:241-249
119. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hoshberg MC et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-1528
120. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF et al. (2000) Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomised controlled trial. Celecoxib Long-term Arthritis Study. JAMA 284:1247-1255
121. Chan F K L GD (2004) Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - Review and recommendations based on risk assessment. Aliment Pharmacol Ther 19:1051-1061
122. Chan F K L, Hung L C T, Suen BY, Wu J C Y, Lee KC, Leung V K S, Hui AJ, To KF, Leung WK, Wong V W S et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104-2110
123. Hawkey JC, Jones IJ, Atherton CT, Slelly MM, Bebb JR, Fagerholm U, Jonzon B, Karlson P, Bjarnason IT (2003) Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 52:1537-1542
124. Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ (1986) The effect of NSAIDs and prostaglandins on the permeability of the human small intestine. Gut 27:1292-1297
125. Bjarnason I, Smethurst P, Fenn GC, Lee CF, Menzies IS, Levi AJ (1989) Misoprostol reduces indomethacin induced changes in human small intestinal permeability. Dig Dis Sci 34:407-411
126. Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ (1991) The importance of local versus systemic effects of non-steroidal anti-inflammatory drugs to increase intestinal permeability in man. Gut 32:275-277
127. Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, Bjarnason I (2000) COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 47:527-532
128. Smecuol E, Sugai E, Maurino E, Vazquez H, Niveloni S, Pedreira S, Meddings J (1998) Gastrointestinal permeability to non-steroidal anti-inflammatory drugs: A prospective study comparing meloxicam to slow release indomethacin. Preliminary results. Gastroenterology 114:A1087
129. Smecuol E, Bai JC, Sugai E, Vazquez H, Niveloni S, Pedreira S, Maurino E, Meddings J (2001) Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 49:650-655
130. Sigthorsson G, Tibble J, Hayllar J, Menzies I, Macpherson A, Moots R, Scott D, MJ G, Bjarnason I (1998) Intestinal permeability and inflammation in patients on NSAIDs. Gut 43:506-511
131. Bjarnason I, Macpherson A J M, Hollander D (1995) Intestinal permeability: An overview. Gastroenterology 108:1566-1581
132. Bjarnason I, Smethurst P, Clarke P, Menzies IS, Levi AJ, Peters TJ (1989) Effect of prostaglandins on indomethacin induced increased intestinal permeability in man. Scand J Gastroenterol 29(suppl 164):97-103
133. Goldstein JL, Eisen G, Lewis B, Gralnek I, Fort JG, Zlotnick S (2003) Celecoxib is associated with fewer small bowel lesions than naproxen + omeprazole in healthy subjects as determined by capsule enteroscopy. Gut 52 (suppl 4):A16
134. Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, De Lacey G, Gumpel MJ, Levi AJ (1987) Nonsteroidal antiinflammatory drug induced intestinal inflammation in humans. Gastroenterology 93:480-489
135. Morris AJ, Madhok R, Sturrock RD, Capell HA, Mackenzie JF (1991) Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal antiinflammatory drugs. Lancet (1) 337:520
136. Bjarnason I, Zanelli G, Prouse P, Smethurst P, Levi S, Gumpel MJ, Levi AJ (1987) Blood and protein loss via small intestinal inflammation induced by nonsteroidal anti-inflammatory drugs. Lancet 2:711-714
137. Hayllar J, Price AB, Smith T, Macpherson A, Gumpel MJ, Bjarnason I (1994) Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss: effect of sulphasalazine and other disease modifying drugs. Arthritis Rheum 37:1146-1150
138. Bjarnason I, Hopkinson N, Zanelli G, Prouse P, Gumpel MJ, Levi AJ (1990) The treatment of non-steroidal anti-inflammatory drug induced enteropathy. Gut 31:777-780
139. Bjarnason I, Hayllar J, Smethurst P, Price AB, Menzies IS, Gumpel MJ (1992) Metronidazole reduces inflammation and blood loss in NSAID enteropathy. Gut 33:1204-1208
140. Morris AJ, Murray L, Sturrock RD, Madhok R, Capell HA, Mackenzie JF (1994) Short report: The effect of misoprostol on the anaemia of NSAID enteropathy. Aliment Pharmacol Ther 8:343-346
141. Langman M J S, Morgan L, Worrall A (1985) Use of anti-inflammatory drugs by patients with small or large bowel perforation and haemorrhage. Br Med J 290:347-349
142. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI (1992) Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 327:749-754
143. Bjarnason I, Macpherson A (1994) Treatment of nonsteroidal antiinflammatory drug induced damage to the small and large intestine. In: TM Bayless (Ed.): Current Therapy in Gastroenterology and Liver Disease (4th Ed.) Mosby, St Louis, 295-298
144. Bjarnason I, Zanelli G, Smethurst P, Burke M, Gumpel MJ, Price AB, Levi AJ (1988) Clinico-pathological features of nonsteroidal antiinflammatory drug induced small intestinal strictures. Gastroenterology 94:1070-1074
145. Lang J, Price AB, Levi AJ, Burk M, Gumpel JM, Bjarnason I (1988) Diaphragm disease: The pathology of non-steroidal anti-inflammatory drug induced small intestinal strictures. J Clin Path 41:516-526
146. Whitcombe DC, Martin SP, Trellis DR, Evans BA, Beicich MJ (1992) "Diaphragmlike" stricture and ulcer of the colon during diclofenac treatment. Arch Int Med 152:2341-2343
147. Speed CA, Bramble MG, Corbett WA, Haslock I (1994) Non-steroidal anti-inflammatory induced diaphragm disease of the small intestine: complexities of diagnosis and management. Br J Rheumatol 33:778-780
148. McCune KH, Allen D, Cranley B (1992) Small bowel diaphragm disease-Strictures associated with non-steroidal anti-inflammatory drugs. Ulster Med J 61:182-184
149. Levi S, De Lacey G, Price AB, Gumpel MJ, Levi AJ, Bjarnason I (1990) 'Diaphragm like' strictures of the small bowel in patients treated with non-steroidal anti-inflammatory drugs. Br J Radiol 63:186-189
150. Hershfield NB (1992) Endoscopic description of diaphragm disease induced by nonsteroidal anti-inflammatory drugs. Gastroint Endosc 38:267
151. Halter F, Weber B, Huber T, Eigenmann F, Frey M, Rutchi C (1993) Diaphragm disease of the ascending colon associated with sustained release diclofenac. J Clin Gastroenterol 16:74-80
152. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C (2003) Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124:288-292
153. Goldstein JL, Bjarnason I, Eisen G, Lewis B (2004) Serious lower bowel complications of NSAIDs in the CLASS study. Gastroenterology 126 (Suppl.2):A1
154. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568
155. Blain H, Boileau C, Laqicque F, Nedelec E, Laeuille D, Guillaume C, Gaucher A, Jeandel C, Netter P, Jy J (2002) Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol 53:255-265
156. Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, Smolen J, Breedveld F, Day R, Dougados M et al. (1999) Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 38:779-788
157. Wight NJ, Gottesdiener K, Garlick NM, Atherton CT, Novak S, Gertz BJ, Calder NA, Cote J, Wong P, Dallob A et al. (2001) Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology 120:867-873
158. Atherton C, Jones J, Kc Kaig B, Bebb J, Cunliffe R, Burdsall J, Brough J, Stevenson D, Bonner J, Rodorf C et al. (2004) Pharmacology and gastrointestinal safety of lumiracoxib, a novel syslooxygenase-2 selective inhibitor: An integrated study. Clin Gastroenterol Hepatol 2:113-120
159. Cipollini F, Mecozzi V, Altilia F (1989) Endoscopic assessmsnt of the effects of nimesulide on the gastric mucosa: Comparison with Indomethacin. Curr Ther Res 45:1042-1049
160. Marini U, Spotti D (1993) Gastric tolerability of nimesulide. A double blind comparison of 2 oral damage regimens and placebo. Drugs 46(suppl 1):249-252
161. Porto A, Reis C, Perdigoto R, Concalves M, Freitas P, Macciocchi A (1998) Gastroduodenal tolerability of nimesulide and diclofenac in patients with osteoarthritis. Curr Ther Res 59:654-665
162. Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B (2003) The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 98:1725-1733
163. Hunt RH, Harper S, Callegary P, Yu C, Quan H, Evans J, James C, Bowen B, Rashid F (2003) Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 17:201-210
164. Gleeson M, Ramsey D, Hutchinson S, Spencer D, Montieth G (1994) Colitis associated with non-steroidal anti-inflammatory drugs. Lancet 344:1028
165. Gleeson MH, Davis AJ (2003) Non-steroidal anti-inflammatory drugs, aspirin and newly diagnosed colitis: a case-control study. Aliment Pharmacol Ther 17:817-825
166. Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K (1990) Eicosanoids in inflammatory bowel disease - physiology and pathology In: TJ Peters (Ed.): The Cell Biology of Inflammation in the Gastrointestinal Tract. Corners Publication, Hull, 255-271
167. Campieri M, Franchi L G A, Bazzocchi G, Brignola C, Benatia B, Boccia S, Labo G (1980) Prostaglandins, indomethacin and ulcerative colitis. Gastroenterology 78:193
168. Rampton DS, Sladen GE (1981) Relapse of ulcerative proctocolitis during treatment with NSAID. Postgrad Med J 57:297-299
169. Kaufman HJ, Taubin HL (1987) NSAID activate quiescent inflammatory bowel disease. Ann Int Med 107:513-516
170. British Medical Association & Royal Pharmaceutical Society of Great Britain (2002) British National Formulary #43. Pharmaceutical Press, Wallingford
171. Tibble J, Sigthorsson G, Foster R, Scott D, Roseth A, Bjarnason I (1999) Faecal calprotectin: A simple method for the diagnosis of NSAID-induced enteropathy. Gut 45:362-366
172. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Fioster R, Sheerwood R, Fagerhol M, Bjarnason I (2000) A simple method for assessing intestinal inflammation in Crohn's disease. Gut 47:506-513
173. Tibble J, Sigthorsson G, Fagerhol M, Bjarnason I (2000) Surrogate markers of intestinal inflammation are predictive for relapse in patients with inflammatory bowel disease. Gastroenterology 119:15-22
174. Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koft RS, Shapiro S (1993) Nonsteroidal antiinflammatory drug use in relation to major gastrointestinal bleeding. Clin Pharmacol Ther 53:485-494
175. Henry D, Dobson A, Turner C (1993) Variability in the risk of major gastrointestinal complications from nonsteroidal anti-inflammatory drugs. Gastroenterology 105:1078-1088
176. Langman M J S, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan R F A, Murphy M, Vessey MP, Colin-Jones DG (1994) Risk of bleeding peptic ulcers associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:1075-1078
177. Rodrigues L A G, Jick H (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:769-772
178. Henry D, Lim LL-Y, Rodrigues L A G, Gutthann PS, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C et al. (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 312:1563-1566
179. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, McDevitt DG (1997) Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study. Br Med J 315:1333-1337
180. Larrey D, Pageaux GP (2005) Drug-induced acute liver failure. Eur J Gastroenterol Hepatol 17:141-143
181. Andrade RJ, Camargo R, Lucena MI, Gonzalez-Grande R (2004) Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 3:329-344
182. Croft AM, Whitehouse DP, Cook GC, Beer MD (2002) Safety evaluation of the drugs available to prevent malaria. Expert Opin Drug Saf 1:19-27
183. Lucena MI, Carvajal A, Andrade RJ, Velasco A (2003) Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf 2:249-262
184. Liu ZX, Kaplowitz N (2002) Immune-mediated drug-induced liver disease. Clin Liver Dis 6:467-486
185. Hartleb M, Biernat L, Kochel A (2002) Drug-induced liver damage - A three-year study of patients from one gastroenterological department. Med Sci Monit 8:CR292-296
186. Marino G, Zimmerman HJ, Lewis JH (2001) Management of drug-induced liver disease. Curr Gastroenterol Rep 3:38-48
187. Degott C (1997) Drug-induced liver injury. Cholestatic injury, acute and chronic. Pathol Oncol Res 3:260-263
188. Biour M, Poupon R, Grangé JD, Chazouilleres O (2000) Hépatotoxicité des médicaments. Gastroenterol Clin Biol 11:1052-1091
189. Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474-485
190. Zimmerman HJ (1998) Drug-induced liver injury - clinical. In: Clinical and Pathological Correlations in Liver Disease: Approaching the Next Millennium. American Association for the Study of Liver Diseases Postgraduate Course, 252-268.
191. ® Healthcare Series, Vol. 121
192. Larrey D (2000) Drug-induced liver diseases. J Hepato 32(Suppl 1):77-88
193. Vandenbroucke JP (2001) In defence of case reports and case series. Ann Intern Med 134:330-334
194. Striker BHCh, Psaty BM (2004) Detection, verification and quantification of adverse drug reactions Br Med J 329:44-47
195. Bessone F, Fay F, Vorobioff J, Passamonti ME, Godoy A, Tanno H (1997) Nimesulide hepatotoxicity: Evidence from six cases. Hepatology 26:483A
196. Carniato A, Vaglia A (1997) Hepatitis-like syndrome induced by nimesulide? Le infezioni in Medicina 4:265
197. Van Steenberger W, Roskams T, Desmet V (1997) Nimesulide-induced acute hepatitis: Evidence from three cases. Gastroenterology 112 (suppl):A1407
198. Grignola JC, Arias L, Rondan M, Sola L, Bagnulo H (1998) Hepatoxicity associated to nimesulide (Revision of five cases) Arch Med Int 20:13-18
199. Selig J, Liberek C, Kondo Oestreicher M, Desmeules J, Stoller R (1998) Nimesulid hepatotoxicity. Poster presented at the 6th Annual Meeting of the European Society of Pharmacovigilance - Budapest, September 28-29
200. Bakhle YS (1999) Nimesulide and COX-2 inhibitors. Lancet 354:772
201. Malhotra S, Pandhi P (2000) Analgesics for pediatric use. Indian J Pediatr 67:589-590
202. Carvajal A, Macia MA, Del Pozo JG, De Abajo F (2003) Small risk ratios may have strong public health impact. Br Med J 327:1050-1051
203. Romero Gomez M, Nevado Santos M, Fobelo MJ, Castro Fernandez M (1999) Hepatitis aguda por nimesulida: descripcion de tres casos. Medicina Clinica 113:357-358
204. Teoh NC, Farrell GC (2003) Hepatotoxicity associated with nonsteroidal anti-inflammatory drugs. Clin Liver Dis 7:401-413
205. Lewin S (2002) Post-marketing surveillance of nimesulide suspension. Indian Pediatr 39:890-891
206. Bessone F, Tanno H (2000) Hepatotoxicidad inducida por antiinflamatorios no esteroides. Gastroenterol Hepatol 23:200-205
207. Andrade RJ, Lucena MI, Fernandez MC, Gonzalez M (2000) Fatal hepatitis associated with nimesulide. J Hepatol 32:174
208. Perez Moreno, Llerena Guerrero RM, Puertas Montenegro M, Jimenez Arjona MJ (2000) Hepatitis toxica en gestante por nimesulide. Gastroenterol Hepatol 23:498-499
209. Papaioannides D, Korantzopoulos P, Athanassiou E, Sinapidis D (2003) Nimesulideinduced acute hepatotoxicity. Indian J Gastroenterol 22:239
210. Lacroix I, Lapeyre-Mestre M, Bagheri H, Pathak A, Montastruc JL; Club de Reflexion des cabinets de Groupe de Gastro-Enterologie (CREGG); General Practitioner Networks (2004) Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. Fundam Clin Pharmacol 18:201-206
211. Tejos SC, Torrejon NS, Rey H, Meneses MC (2000) Ulceras gástricas sangrantes y hepatitis aguda: dos reacciones adversas simultáneas por nimesulida, en un caso. Rev Méd Chile 128:1349-1353
212. Dourakis SP, Sevastianos VA, Petraki K, Hadziyannis SJ (2001) Nimesulide induced acute icteric hepatitis. Iatriki 79:275-278
213. Castaneda Hernandez G, Barragan Padilla SB (2004) Hepatotoxicity of nimesulide Gac Med Mex 140:679 [Spanish]
214. Montesinos S, Hallal H, Rausell V, Conesa FJ, Lopez A (2001) Hepatitis aguda por nimesulida. Gastroenterol Hepatol 24:219-220
215. Quadranti P (2000) Acute hepatitis after use of nimesulide: drug-induced or is there something more? Mononucleosis. Schweiz Rundsch Med Prax 93:1785-1787 [German]
216. Dumortier J, Borel I, Delafosse B, Vial T, Scoazec JY, Boillot O (2002) Transplantation hépatique pour hépatite subfulminante après prise de Nimesulide. Gastroentrol Clin Biol 26:415-416
217. Gallego Rojo FJ, Fernandez Perez F, Fernandez Perez R, Porcel A, Blas JM, Diez F (2002) Hepatotoxicidad por nimesulida. Rev Esp Enferm Dig 94:41-42
218. Rodrigo L, De Francisco R, Perez-Pariente JM, Cadahia V, Tojo R, Rodriguez M, Lucena MI, Andrade RJ (2002) Nimesulide-induced severe hemolytic anemia and acute liver failure leading to liver transplantation. Scand J Gastroenterol 37:1341-1343
219. Stadlmann S, Zoller H, Vogel W, Offner FA (2002) COX-2 inhibitor (nimesulide) induced acute liver failure. Virchows Arch 440:553-555
220. Ozgur O, Hacihasanoglu A, Karti SS, Ovali E (2003) Nimesulide-induced fulminant hepatitis. Turk J Gastroenterol 14:208-210
221. Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of International Consensus Meetings: application to drug-induced liver injuries. J Clin Epidemiol 46:1323-1330
222. ® online, version 12.1
223. Ishak KG (1998) Drug-induced liver injury - Pathology. In: Clinical and Pathological Correlations in Liver Disease: Approaching the Next Millennium. American Association for the Study of Liver Diseases Postgraduate Course, 236-251
224. Goodman ZD (2002) Drug hepatotoxicity. Clin Liver Dis 6:381-397
225. Rainsford KD (2003) Analyses of adverse drug reactions attributed to nimesulide worldwide with particular reference to those in the hepatic body system. Helsinn Internal Report TSD No. 8104
226. Weber J C P (1984) Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: KD Rainsford, GP Velo (eds): Side-Effects of Antiinflammatory Drugs. Raven Press, New York, 1-7
227. Velayudham LS, Farrell GC (2003) Drug-induced cholestasis. Expert Opin Drug Saf 2:287-304
228. Kistner RW (1971) Present status of oral contraceptives: 1. Effectiveness; basis for selection; side effects; metabolic changes. Drug Ther (NY) 1:14-29
229. Dourakis SP, Tolis G (1998) Sex hormonal preparations and the liver. Eur J Contracept Reprod Health Care 3:7-16
230. Lindgren A, Olsson R (1993) Liver damage from low-dose oral contraceptives. J Intern Med 234:287-292
231. Zacur HA, Stewart D (1992) New concepts in oral contraceptive pill use. Curr Opin Obstet Gynecol 4:365-371
232. Adlin EV (1979) Postmenopausal estrogen therapy. Ann Intern Med 91:488-489
233. Blau SP (1977) Study Report R-805-010-02. Helsinn Internal Report TSD No. 7344
234. Russell AJ, Sturge RA, Smith MA (1971) Serum transaminases during salicylate therapy. Br Med J 2:428-429
235. Seaman WE, Ishak KG, Plotz PH (1974) Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med 80:1-8
236. Seaman WE, Plotz PH (1976) Effect of aspirin on liver tests in patients with RA or SLE and in normal volunteers. Arthritis Rheum 19:155-160
237. Wolfe JD, Metzger AL, Goldstein RC (1974) Aspirin hepatitis. Ann Intern Med 30:74-76
238. Zimmerman HJ (1981) Effect of aspirin and acetaminophen on the liver. Ann Intern Med 141:333-342
239. Prescott LF (1992) The hepatotoxicity of non-steroidal anti-inflammatory drugs. In: KD Rainsford, GP Velo (eds): Side-effects of Anti-inflammatory Drugs 3. Kluwer Academic Publishers, Dordrecht, 176-187
240. Banks AT, Zimmerman HJ, Ishak KG, Harter JG (1995) Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 22:820-827
241. Zucker P, Daum F, Cohen MI (1975) Aspirin hepatitis. Am J Dis Child 129:1433-1434
242. Huuponen R, Helin-Salmivaara A, Klaukka T (2003) Heavy users of NSAIDs in Finland. A prescription database study. In: 6th Congress of the European Association for Clinical Pharmacology and Therapeutics. Istanbul, Turkey, June 24-28, Abstract No. P-133
243. Lewis JH (2002) The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf 1:159-172
244. Parra JL, Reddy KR (2003) Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 7:415-433
245. Heerey A, Barry M, Ryan M, Kelly A (2000) The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 169:176-179
246. Simpura J, Tigerstedt C, Hanhinen S, Lagerspetz M, Leifman H, Moskalewicz J, Torronen J (1999) Alcohol misuse as a health and social issue in the Baltic Sea region. A summary of findings from the Baltica Study. Alcohol Alcohol 34:805-823
247. Dreyer L, Winther JF, Andersen A, Pukkala E (1997) Avoidable cancers in the Nordic countries. Alcohol consumption. APMIS 76(suppl):48-67
248. Anonymous (2000) Alcohol Consumption and Harm in the UK and EU. IAS Factsheet. Institute of Alcohol Studies, St Ives (Cambridge)
249. Perola M, Vuori E, Penttila A (1994) Abuse of alcohol in sudden out-of-hospital deaths in Finland. Alcohol Clin Exp Res 18:255-260
250. Seppa K, Lof K, Sinclair D, Sillanaukee P (1994) Hidden alcohol abuse among women. Br J Psychiatry 164:544-546
251. Seppa K, Sillanaukee P, Koivula T (1990) The efficiency of a questionnaire in detecting heavy drinkers. Br J Addict 85:1639-1645
252. Agren G, Romelsjo A (1992) Mortality in alcohol-related diseases in Sweden during 1971-80 in relation to occupation, marital status and citizenship in 1970. Scand J Soc Med 20:134-142
253. Hakulinen T, Lehtimaki L, Lehtonen M, Teppo L (1974) Cancer morbidity among two male cohorts with increased alcohol consumption in Finland. J Natl Cancer Inst 52:1711-1714
254. Keso L, Kivisaari A, Salaspuro M (1988) Fractures on chest radiographs in detection of alcoholism. Alcohol Alcoholism 23:53-56
255. Koskenvuo M, Kaprio J, Kesaniemi A, Poikolainen K (1986) Alcohol-related diseases associated with ischaemic heart disease: a three-year follow-up of middle-aged male hospital patients. Alcohol Alcoholism 21:251-256
256. Laitinen K, Valimaki M, Lamberg-Allardt C, Kivisaari L, Lalla M, Karkkainen M, and Ylikahri R (1990) Deranged vitamin D metabolism but normal bone mineral density in Finnish noncirrhotic male alcoholics. Alcohol Clin Exp Res 14:551-556
257. Olkinuora M (1984) Alcoholism and occupation. Scand J Work Environ Health 10:511-515
258. Penttila A (1980) Sudden and unexpected natural deaths of adult males. An analysis of 799 forensic autopsies in 1976. Forensic Sci Int 16:249-259
259. Poikolainen K (1983) Accuracy of hospital discharge data: five alcohol-related diseases. Drug Alcohol Depend 12:315-322
260. Poikolainen K (1982) Seasonality of alcohol-related hospital admissions has implications for prevention. Drug Alcohol Depend 10:65-69
261. Valimaki MJ, Laitinen K, Tiitinen A, Steman UH, and Ylostalo P (1995) Gonadal function and morphology in non-cirrhotic female alcoholics: A controlled study with hormone measurements and ultrasonography. Acta Obstet Gynecol Scand 74:462-466
262. Pikkarainen P (1978) The liver, alcohol and women. Duodecim 94:620-622 [in Finnish]
263. Savolainen VT Penttila A, Karhunen PJ (1992) Delayed increases in liver cirrhosis mortality and frequency of alcoholic liver cirrhosis following an increment and redistribution of alcohol consumption in Finland: evidence from mortality statistics and autopsy survey covering 8533 cases in 1968-1988. Alcohol Clin Exp Res 16:661-664
264. Savander M, Ropponen A, Avela K, Weerasekera N, Cormand B, Hirvioja ML, Riikonen S, Ylikorkala O, Lehesjoki AE, Williamson C et al. (2003) Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. Gut 52:1025-1029
265. Koivurova S, Hartikainen AL, Karinen L, Gissler M, Hemminki E, Martikainen H, Tuomivaara L, Jarvelin MR (2002) The course of pregnancy and delivery and the use of maternal healthcare services after standard IVF in Northern Finland 1990-1995. Hum Reprod 17:2897-2903
266. Eloranta ML, Heiskanen JT, Hiltunen MJ, Mannermaa AJ, Punnonen KR, Heinonen ST (2002) Multidrug resistance 3 gene mutation 1712delT and estrogen receptor alpha gene polymorphisms in Finnish women with obstetric cholestasis. Eur J Obstet Gynecol Reprod Biol 105:132-135
267. Reyes H, Baez ME, Gonzalez MC, Hernandez I, Palma J, Ribalta J, Sandoval L, Zapata R (2000) Selenium, zinc and copper plasma levels in intrahepatic cholestasis of pregnancy, in normal pregnancies and in healthy individuals, in Chile. J Hepatol 32:542-549
268. Pasanen P, Partanen K, Pikkarainen P, Alhava E (1992) Characteristics of jaundice and cholestasis in a Finnish population. Ann Chir Gynaecol 81:284-289
269. Fusi D, Corsello FP, Piacentino R, Marchino GL, Grio R (1993) Cholestasis in pregnancy. Minerva Ginecol 45:307-314 [in Italian]
270. Hirvioja ML, Tuimala R, Vuori J (1992) The treatment of intrahepatic cholestasis of pregnancy by dexamethasone. Br J Obstet Gynaecol 99:109-111
271. Eloranta ML, Hakli T, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S (2003) Association of single nucleotide polymorphisms of the bile salt export pump gene with intrahepatic cholestasis of pregnancy. Scand J Gastroenterol 38:648-652
272. Eloranta ML, Heiskanen JT, Hiltunen MJ, Mannermaa AJ, Punnonen KR, Heinonen ST (2002) Multidrug resistance 3 gene mutation 1712delT and estrogen receptor alpha gene polymorphisms in Finnish women with obstetric cholestasis. Eur J Obstet Gynecol Reprod Biol 105:132-135
273. Eloranta ML, Heiskanen JT, Hiltunen MJ, Mannermaa AJ, Punnonen KR, Heinonen ST (2002) Multidrug resistance 3 gene mutation 1712delT and estrogen receptor alpha gene polymorphisms in Finnish women with obstetric cholestasis. Eur J Obstet Gynecol Reprod Biol 104:109-112
274. Eloranta ML, Heinonen S, Mononen T, Saarikoski S (2001) Risk of obstetric cholestasis in sisters of index patients. Clin Genet 60:42-45
275. Heinonen S, Eloranta ML, Heiskanen J, Punnonen K, Helisalmi S, Mannermaa A, Hiltunen M (2001) Maternal susceptibility locus for obstetric cholestasis maps to chromosome region 2p13 in Finnish patients. Scand J Gastroenterol 36:766-770
276. Eloranta ML, Heiskanen J, Hiltunen M, Helisalmi S, Mannermaa A, Heinonen S (2000) Apolipoprotein E alleles in women with intrahepatic cholestasis of pregnancy. Scand J Gastroenterol 35:966-968
277. Bergmann C, Senderek J, Sedlacek B, Pegiazoglou I, Puglia P, Eggermann T, Rudnik-Schoneborn S, Furu L, Onuchic LF, De Baca M et al. (2003) Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1) J Am Soc Nephrol 14:76-89
278. Tahvanainen E, Tahvanainen P, Kaariainen H, Hockerstedt K (2004) Genetic defects underlying polycystic liver disease are discovered. Duodecim 20:1081-1084
279. Drenth JP, Tahvanainen E, Te Morsche RH, Tahvanainen P, Kaariainen H, Hockerstedt K, Van De Kamp JM, Breuning MH, Jansen JB (2004) Abnormal hepatocystin caused by truncating PRKCSH mutations leads to autosomal dominant polycystic liver disease. Hepatology 39:924-931
280. Tahvanainen P, Tahvanainen E, Reijonen H, Halme L, Kaariainen H, Hockerstedt K (2003) Polycystic liver disease is genetically heterogeneous: Clinical and linkage studies in eight Finnish families. J Hepatol 38:39-43
281. Todorova B, Kubaszek A, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J et al. Finnish Diabetes Prevention Study (2004) The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: The Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 89:2019-2023
282. Connelly PW, Hegele RA (1998) Hepatic lipase deficiency. Crit Rev Clin Lab Sci 35:547-572
283. Tahvanainen E, Syvanne M, Frick MH, Murtomaki-Repo S, Antikainen M, Kesaniemi YA, Kauma H, Pasternak A, Taskinen MR, Ehnholm C (1998) Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Investigators. J Clin Invest 101:956-960
284. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H (2003) Finnish Treat-to-Target Study Investigators Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 141:131-137
285. Jarvelainen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO (2001) Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 33:1148-1153
286. Savolainen VT, Pajarinen J, Perola M, Penttila A, Karhunen PJ (1997) Polymorphism in the cytochrome P450 2E1 gene and the risk of alcoholic liver disease. J Hepatol 26:55-61
287. Liiv I, Teesalu K, Peterson P, Clemente MG, Perheentupa J, Uibo R (2002) Epitope mapping of cytochrome P450 cholesterol side-chain cleavage enzyme by sera from patients with autoimmune polyglandular syndrome type 1. Eur J Endocrinol 146:113-119
288. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A (2000) Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 9:1343-1348
289. Levo A, Jaaskelainen J, Sistonen P, Siren MK, Voutilainen R, Partanen J (1999) Tracing past population migrations: genealogy of steroid 21-hydroxylase (CYP21) gene mutations in Finland. Eur J Hum Genet 7:188-196
290. Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, Nikkila H, White PC (1998) Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 97:569-575
291. Hirvonen A (1999) Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer. Environ Health Perspect 107(suppl 1):37-47
292. Hirvonen A (2003) Combinations of susceptible genotypes and individual responses to toxicants. Environ Health Perspec 105(suppl 4):755-758
293. Levo A, Koski A, Ojanpera I, Vuori E, Sajantila A (2003) Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci Int 135:9-15
294. Tiitinen H (1969) Isoniazid and ethionamide serum levels and inactivation in Finnish subjects. Scand J Respir Dis 50:110-124
295. Helske T (1974) Carriers of hepatitis B antigen and transfusion hepatitis in Finland. Scand J Haematol Suppl 22:1-65
296. Hokkanen OT and Sotaniemi EA (1978) Liver injury and multiple drug therapy. Arch Toxicol Suppl 173-176
297. Leino T, Leinikki P, Hyypia T, Ristola M, Suni J, Sutinen J, Holopainen A, Haikala O, Valle M, Rostila T (1997) Hepatitis A outbreak amongst intravenous amphetamine abusers in Finland. Scand J Infect Dis 29:213-216
298. Pohjanpelto P (1992) Risk factors connected with hepatitis C infections in Finland. Scand J Infect Dis 24:251-252
299. Sinkkonen S, Rantalainen AL, Paasivirta J, Lahtipera M (2004) Polybrominated methoxy diphenyl ethers (MeO-PBDEs) in fish and guillemot of Baltic, Atlantic and Arctic environments. Chemosphere 56:767-775
300. Lamminpaa A, Pukkala E, Teppo L, Neuvonen PJ (2002) Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28, 000 patients. Eur J Clin Pharmacol 58:137-141
301. Swingle KF, Moore G G I (1984) Preclinical pharmacological studies with nimesulide. Drugs Exptl Clin Res 10:597-597
302. Swingle KF, Moore G G I, Grant TJ (1976) 4-Nitro-2-phenoxymethanesulfonanilide (R-805): A chemically novel anti-inflammatory agent. Achiv int Pharmacodyn 221:132-139
303. Rainsford KD (1975) A synergistic interaction between aspirin, or other non-steroidal anti-inflammatory drugs, and stress which produces severe gastric mucosal damage in rats and pigs. Agents Actions 5:553-558
304. Rainsford KD (1975) Studies on the effects of R-805 on the gastro-intestinal tract of domestic pigs - A model for the study of human gastro-intestinal functions and ulcer disease. Unpublished studies
305. Rainsford KD (1977) Towards assays of gastrointestinal toxicity of non-steroidal antiinflammatory drugs with improved predictive value in man. Agents Actions 7:245-248
306. Rainsford KD (1981) Comparison of the gastric ulcerogenic activity of new nonsteroidal anti-inflammatory drugs in stressed rats. Br J Pharmacol 73:79c-80c
307. Rainsford KD and Willis C (1982) Relationship of gastric mucosal damage induced in pigs by anti-inflammatory drugs to their effects on prostaglandin production. Dig Dis Sci 27:624-635
308. Rainsford KD (1982) An analysis of the gastro-intestinal side-effects of non-steroidal anti-inflammatory drugs, with particular reference to comparative studies in man and laboratory species. Rheumatol Internat 2:1-10
309. Rainsford KD (1985) Relationships of gastric irritancy/ulcerogenicity and anti-oedemic activity of non-steroidal anti-inflammatory drugs. J Pharm Pharmacol 37:678-679
310. Rainsford KD (1989) Animal models for the assay of gastrointestinal toxicity of anti-inflammatory drugs. In: RA Greenwald, HS Diamond (eds): CRC Handbook of Animal Models for the Rheumatic Diseases. CRC Press, Boca Raton, Florida, 181-206
311. Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C, Tanako S (1992) Pharmacological studies of the new anti-inflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st Communication: Antiinflammatory, analgesic and other related properties. Arzneim Forsch 42:935-944
312. Tanaka K, Makino S, Shimotori T, Aikawa Y, Inaba T, Yoshida C (1992) Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4'-1-benzopyran-4-one. 2nd communication: Effect on the arachidonic acid cascades. Arzneim Forsch 42:945-950
313. Rainsford KD, Fox SA, Osborne, DJ (1984) Comparative effects of some non-steroidal anti-inflammatory drugs on the ultrastructural integrity and prostaglandin levels in the rat gastric mucosa: Relationship to drug uptake. Scand J Gastroenterol 19(suppl 101):55-68
314. Rainsford KD (1986) Structural damage and changes in eicosanoid metabolites in the gastric mucosa of rats and pigs induced by anti-inflammatory drugs of varying ulcerogenicity. Int J Tiss React 8:1-14
315. Rainsford KD (1988) Comparative irritancy of oxaprozin on the gastrointestinal tract of rats and mice: Relationship to drug uptake and effects in vivo on eicosanoid metabolism. Aliment Pharmacol Therap 2:439-450
316. Nakatsugi S, Terada N, Yoshimura T, Horie Y, Furukawa M (1996) Effects of nimesulide, a preferential cyclooxygenase-2 inhibitor, an carrageenan-induced pleurisy and stress-induced gastric lesions in rats. Prost Leuk Essential Fatty Acids 55:395-402
317. Laudanno OM, Cesolari JA, Esnarriaga J, San Miguel P, and Bedini OA (2000) In vivo selectivity of nonsteroidal antiinflammatory drugs and gastrointestinal ulcers in rats. Dig Dis Sci 45:1359-1365
318. Tavares IA, Bishai PM, Bennett A (1995) Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneim Forsch 45:1093-1095
319. Cryer B, Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104:413-421
320. Kataoka H, Horie Y, Koyama R, Nakatsugi S, and Furukawa M (2000) Interaction between NSAIDs and steroid in rat stomach: safety of nimesulide as a preferential COX-2 inhibitor in the stomach. Dig Dis Sci 45:1366-1375
321. Tofanetti O, Casciarri I, Cipolla PV, Cazzlani P, Omini C (1989) Effect of nimesulide on cyclooxygenase activity in rat gastric mucosa and inflammatory exudates. Med Sci Res 17:745-746
322. Ceserani R, Casciarri I, Cavaletti E, Cazzulani P (1991) Action of nimesulide on rat gastric prostaglandins and renal function. Drug Invest 3(suppl 2):14-21
323. Sigthorsson G, Jacob M, Wrigglesworth J, Somasundaram S, Tavares I, Foster R, Roseth A, Rafi S, Mahmud T, Simpson R et al. (1998) Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in the rat. Scand J Gastroenterol 33:728-735
324. Shah AA, Murray FE, Fitzgerald DJ (1999) The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. Rheumatology (Oxford) 38(suppl 1):19-23
325. 2 generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach. Pharmacology 61:244-250
326. Hirata T, Ukawa H, Yamakuni H, Kato S, and Takeuchi K (1997) Cyclo-oxygenase isozymes in mucosal ulcerogenic and functional responses following barrier disruption in rat stomachs. Br J Pharmacol 122:447-454
327. Hirata T, Ukawa H, Kitamura M, Takeuchi K (1997) Effects of selective cyclooxygenase-2 inhibitors on alkaline secretory and mucosal ulcerogenic responses in rat duodenum. Life Sci 61:1603-1611
328. Suleyman H, Altinkaynak K, Gocer F, Maras A, Akcay F, Onuk MD, Gepdiremen A (2002) Effect of nimesulide on the indomethacin- and ibuprofen-induced ulcer in rat gastric tissue. Pol J Pharmacol 54:255-259
329. Altinkaynak K, Suleyman H, Akcay F (2003) Effect of nimesulide, rofecoxib and celecoxib on gastric tissue glutathione level in rats with indomethacin-induced gastric ulcerations. Pol J Pharmacol 55:645-648
330. Rainsford KD (2001) The ever-emerging anti-inflammatories. Have there been any real advances? J Physiol Paris 95:11-19
331. Suleyman H, Akcay F, and Altinkaynak K (2002) The effect of nimesulide on the indomethacin- and ethanol-induced gastric ulcer in rats. Pharmacol Res 45:155-158
332. Ramesh N, Jayakumar K, Narayana HK, Vijayasarathi SK (2001) Nimesulide toxicity in dogs. Indian J Pharmacol 33:217-218
333. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, and Simmons DL (2004) Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res 65:810-818
334. Toutain PL, Cester CC, Haak T, Laroute V (2001) A pharmacokinetic/pharmacodynamic approach versus a dose titration for the determination of a dosage regimen: the case of nimesulide, a Cox-2 selective nonsteroidal anti-inflammatory drug in the dog. J Vet Pharmacol Therap 24:43-55
335. Toutain PL, Cester CC, Haak T, Metge S (2001) Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. J Vet Pharmacol Therap 24:35-42
336. Tavares IA, Borrelli F, Welsh NJ (2001) Inhibition of gastric acid secretion by nimesulide: a possible factor in its gastric tolerability. Clin Exp Rheumatol 19:S13-S15
337. Borrelli F, Tavares IA (2003) Effect of nimesulide on gastric acid secretion in the mouse stomach in vitro. Life Sci 72:885-896
338. Moreno-Sanchez R, Bravo C, Vasquez C, Ayala G, Silveira LH, Martinez-Lavin M (1999) Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-Inflammatory drugs - Study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol 57:743-752
339. Caparroz-Assef SM, Salgueiro-Pagadigorria CL, Bersani-Amado CA, Bracht A, Kelmer-Bracht AM, Ishii-Iwamoto EL (2001) The uncoupling effect of the nonsteroidal anti-Inflammatory drug nimesulide in liver mitochondria from adjuvant-induced arthritic rats. Cell Biochem Funct 19:117-124
340. Rainsford KD (2004) Side-effects and toxicology of the salicylates. In: KD Rainsford (Ed.): Aspirin and Related Drugs. CRC Press, Boca Raton, Florida, 367-554
341. Berti F, Rossoni A, Buschi A, Rebeshi M, Villa LM (1990) Antianaphylactic and antihistaminic activity of the non-steroidal anti-inflammatroy compound, nimesulide, in guinea pig. Arneim Forsch 40:1011-1016
342. Casolaro V, Meliota S, Marino O, Patella V, De Paulis A, Guidi G, and Marone G (1993) Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells. J Pharmacol Exp Ther 267:1375-1385
343. Saeed SA, Shah BH (1998) Dual effects of nimesulide, a COX-2 inhibitor, in human platelets. Life Sci 63:1835-1841
344. Chan FK, Hawkey CJ, Lanas AI (2001) Helicobacter pylori and nonsteroidal antiinflammatory drugs: A three-way debate. Am J Med 110(1A):55S-57S
345. Huang JQ, Sridhar S, Hunt RH (2002) Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 359:14-22
346. Hawkey CJ (1999) Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance. Aliment Pharmacol Ther 13:695-702
347. Leung WK, To KF, Chan F K L, Lee TL, Chung S C S, Sung J J Y (2000) Interaction of Helicobacter pylori eradication and non-steroidal anti-inflammatory drugs on gastric epithelial apoptosis and proliferation: implications on ulcerogenesis. Aliment Pharmacol Ther 14:879-885
348. Tatguguchi A, Sakamoto C, Wada K, Akamatsu T, Tsukui T, Miyake K, Futagami S, Kishida T, Fukuda Y, Yamanaka N et al. (2000) Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut 46:782-789
349. Kapicioglu S, Baki AH, Sari M, Ozdemir F, Kavgaci H (2000) Does nimesulide induce gastric mucosal damage? "A double-blind randomized placebo-controlled trial". Hepatogastroenterology 47:1183-1185
350. Guslandi M, Foppa L, Fanti L, Sorghi M (1999) Nonsteroidal anti-inflammatory drugs and gastric mucosal blood flow. J Clin Gastroenterol 28:258-260
351. Li JY, Wang XZ, Chen FL, Yu JP, Luo HS (2003) Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol 9:915-920
352. Jain NK, Kulkarni SK, Singh A (2002) Modulation of NSAID-induced antinociceptive and anti-inflammatory effects by alpha2-adrenoreceptor agonists with gastroprotective effects. Life Sci 70:2857-2869
353. Tardieu D, Jaeg JP, Deloly A, Corpet DE, Cadet J, Petit CR (2000) The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis 21:973-976
354. Oktar BK, Cakir B, Mutlu N, Celikel C, Alican I (2002) Protective role of cyclooxygenase (COX) inhibitors in burn-induced intestinal and liver damage. Burns 28:209-214
355. Zhang L, Lu YM, Dong XY (2004) Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. Chin J Dig Dis 5:110-114
356. Lugering A, Floer M, Lugering N, Cichon C, Schmidt MA, Domschke W, Kucharzik T (2004) Characterization of M cell formation and associated mononuclear cells during indomethacin-induced intestinal inflammation. Clin Exp Immunol 136:232-238
357. Martin AR, Villegas I, La Casa C, Alarcon De La Lastra C (2003) The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. Eur J Pharmacol 481:281-291
358. Barbare JC, Imbert A, Benkirane A (2001) Recent developments concerning druginduced liver toxicity. Presse Medicale 30:673-676
359. Boelsterli UA (2002) Nimesulide and hepatic adverse effects: Roles of reactive metabolites and host factors. Int J Clin Pract Suppl 30-36
360. Boess F, Bopst M, Althaus R, Polsky S, Cohen SD, Eugster HP, Boelsterli UA (1998) Acetaminophen hepatotoxicity in tumour necrosis factor-alpha gene knockout mice. Hepatology 27:1021-2019
361. Boelsterli UA (2003) Animal models of human disease in drug safety assessment. J Toxicol Sci 28:109-121
362. Pishvaian AC, Trope BW, Lewis JH (2004) Drug-induced liver disease in 2003. Curr Opin Gastroenterol 20:208-219
363. Rainsford KD (2005) Analysis of confounding factors in non-steroidal anti-inflammatory drug - Associated adverse events. When are the NSAIDs the culprits? Drug Safety, in preparation
364. Boelsterli UA (2003) Disease-related determinants of susceptibility to drug-induced idiosyncratic hepatotoxicity. Curr Opinion Drug Disc Devel 6:81-91
365. Lewis JH (2002) Drug-induced liver disease. Curr Opin Gastroenterol 18:307-313
366. Liberopoulos EN, Nonni AB, Tsianos EV, Elisaf MS (2002) Possible ranitidine-induced cholestatic jaundice. Ann Pharmacother 36:172
367. Macpherson D, Best SA, Gedik L, Hewson AT, Rainsford KD, Parisi F (2004) The biotransformation and pharmacokinetics in humans of single dose of 14C-nimesulide. Submitted
368. Rainsford KD, Seabrook RW, Spencer S, Hewson AT (2001) Effects of Nimesulide and its metabolites or manufacturing intermediates on the viability and growth of the human hepatoma HepG2 cell line. Life Sciences 69:2965-2973
369. Sohi, KK, Khanduja KL (2003) Nimesulide affects antioxidant status during acute lung inflammation in rats. Indian J Biochem Biophys 40:238-245
370. Caparroz-Assef SM, Bersani-Amado CA, Do Nascimento EA, Kelmer-Bracht AM, Ishii-Iwamoto EL (1998) Effects of the nonsteroidal anti-inflammatory drug nimesulide on energy metabolism in livers from adjuvant-induced arthritic rats. Res Comm Mol Path Pharmacol 99:93-116
371. Mingatto FE, Dos Santos AC, Rodrigues T, Pigoso AA, Uyemura SA, Curti C (2000) Effects of Nimesulide and its reduced metabolite on mitochondria. Br J Pharmacol 131:1154-1160
372. Caparroz-Assef SM, Salgueiro-Pagadigorria CL, Bersani-Amado CA, Bracht A, Kelmer-Bracht AM, Ishii-Iwamoto EL (2001) The uncoupling effect of the nonsteroidal anti-inflammatory drug nimesulide in liver mitochondria from adjuvant-induced arthritic rats. Cell Biochem Funct 19:117-124
373. Mingatto FE, Rodrigues T, Pigoso AA, Uyemura SA, Curti C, Santos AC (2002) The critical role of mitochondrial energetic impairment in the toxicity of nimesulide to hepatocytes. J Pharmacol Exp Ther 303:601-607
374. Whitehouse MW (1965) Some biochemical and pharmacological properties of anti-inflammatory drugs. Arzneim Forsch-Progress in Drug Research 8:321-429
375. Galati G, Tafazoli S, Sabzevari O, Chan TS, O'Brien PJ (2002) Idiosyncratic NSAID drug induced oxidative stress. Chem Biol Interact 142:25-41
376. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398
377. Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302
378. Fantappie O, Masini E, Sardi I, Raimondi L, Bani D, Solazzo M, Vannacci A, Mazzanti R (2002) The Mdr phenotype is associated with the expression of Cox-2 and inos in a human hepatocellular carcinoma cell line. Hepatology 35:843-852
379. Souto EO, Miyoshi H, Dubois RN, Gores GJ (2001) Kupffer cell-derived cyclooxygenase-2 regulates hepatocyte Bcl-2 expression in choledocho-venous fistula rats. Am J Physiol 280:G805-G811
380. Leong R W L, Sung J J Y (2002) Review article: Helicobacter species and hepatobiliary diseases. Aliment Pharmacol Ther 16:1037-1045
381. Rodriguez F, Llinás, Moreno C, Salazar FJ (2001) Role of cyclo-oxygenase-2 derived metabolites and NO in renal response to bradykinin. Hypertension 37:129-134
382. Roig F, Llinás MT, Löpez R, Salazar FJ (2002) Role of cyclo-oxygenase-2 in the prolonged regulation of renal function. Hypertension 40:721-728
383. Steinhäuslin F, Munafo A, Buclin T, Macciocchi A, Biollaz J (1993) Renal effects of nimesulide in furosemide-treated subjects. Drugs 46(suppl 1):257-262
384. Schlondorff D (1993) Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Intern 44:643-653
385. Benini D, Fanos V, Cuzzolin L, Tato L (2004) In utero exposure to anti-inflammatory drugs: Neonatal renal failure. Pediatr Nephrol 19:232-234
386. Gupta P, Sachdev HP (2003) Safety of oral use of niemsulide in children: Systematic review of randomised controlled trials. Indian Pediatr 40:518-531
387. Prevot A, Mosig D, Martini S, Guignard JP (2004) Nimesulide, a cyclooxygenase-2 preferential inhibitor, impairs renal function in the newborn rabbit. Pediatr Res 55:254-260
388. Llinas MT, Lopez R, Rodriguez F, Roig F, Salazar FJ (2001) Role of COX-2-derived metabolites in regulation of the renal hemodynamic response norepinephrine. Am J Physiol Renal Physiol 281:F975-F982
389. Roig F, Llinas MT, Lopez R, Salazar FJ (2002) Role of cyclooxygenase-2 in the prolonged regulation of renal function. Hypertension 40:721-728
390. Lopez R, Llinas MT, Roif F, Salazar FJ (2003) Role of nitric oxide and cyclooxygenase-2 in regulating the renal hemodynamic response to norepinephrine. Am J Physiol Regul Integr Comp Physiol 284(2):R488-R493
391. Eras J, Perazella MA (2001) NSAIDs and the kidney revisited: are selective cyclooxygenase-2 inhibitors safe? Am J Med Sci 321:181-190
392. Quilley J, Chen YJ (2003) Role of COX-2 in the enhanced vasoconstrictor effect of arachidonic acid in the diabetic rat kidney. Hypertension 42:837-843
393. Kanikkannan N, Jackson T, Shaik MS, Singh M (2001) Evaluation of skin sensitisation potential of melatonin and nimesulide by murine local lymph node assay. Eur J Pharm Sci 14:217-220
394. Asero R (1999) Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders. Ann Allergy Asthma Immunol 82:554-558
395. Sanchez Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR (2001) Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 87:201-204
396. Quiralte J, Saenz De San Pedro B, Florido JJ (2002) Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 89:63-66
397. Pastorello EA, Zara C, Riario-Sforza GG, Pravettoni V, Incorvaia C (1998) Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs. Allergy 53:880-884
398. Thawani V, Sontakke S, Gharpure K, Pimpalkhute S (2003) Nimesulide: The Current Controversy. Indian J Pharmacol 35:121-122
399. Kumar S (2003) Drug link to child deaths is still available in India. Br Med J 326:70
400. Saha K (2003) Use of nimesulide in Indian children must be stopped. Br Med J 326:713
401. Gupta P, Sachdev HP (2003) Safety of oral use of nimesulide in children: systematic review of randomized controlled trials. Indian Pediatr 40:518-531
402. jayashreep@expressindia.com (2004) Paediatric nimesulide: Lack of data leads to continued exposure. www.expresspharmapulse.com/print.php?article=391 (16 Sept).